Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
Qvanteq

Category: News

19. June 20127. February 20182012, News

CTI Start-Up Label

Qvanteq AG was awarded with the “CTI Start-Up Label”  in June 2012.

3. April 20127. February 20182012, News

zkb pionierpreis technopark 2012 finalist

Qvanteq was among the finalists of the Pionierpreis 2012. 15 companies have been nominated.

13. January 20127. February 20182012, News

Qvanteq in “20minuten”: “Weniger Herzinfarkte dank neuer Stent-Technologie”

A portrait of Qvanteq AG was published in the the Swiss  journal “20minuten” under the the title “Weniger Herzinfarkte dank neuer Stent-Technologie”.   Full article (g).

27. April 20107. February 20182011 and earlier, News

Series A financing round

Qvanteq AG closed a Series A financing round to achieve proof of concept for its novel stent technology. The round was assisted by investiere.ch through a successful co-funding.

22. March 20107. February 20182011 and earlier, News

Venture Leaders USA Winner

Arik Zucker is one of the winners of the venture leader USA program.

Posts navigation

< 1 … 5 6 7 >

Recent News

  • Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption
  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG